Stryker OP-1 clarification
This article was originally published in The Gray Sheet
Executive Summary
U.S. approval by 2006 for use of the orthobiologic bone growth factor in posterior lateral spine procedures is expected by the company; enrollment in a 300-patient U.S. pivotal trial is ongoing. OP-1 has been available in the U.S. for recalcitrant long bone, non-union fractures via humanitarian device exemption since 2001; the firm also is pursuing a full long-bone indication. In March, "The Gray Sheet" incorrectly reported that OP-1 was not approved for any indication (1"The Gray Sheet" March 31, 2003, p. 33)...
You may also be interested in...
Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search
Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.